Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Rectal Cancer
•
Medical Oncology
•
Colorectal Cancer
•
NCI-CCC Tumor Board Question
•
NCI-CCC GI Tumor Board Question
•
Memorial Sloan Kettering
For patients with rectal cancer being treated along PROSPECT paradigm, would you extrapolate from the IDEA literature and offer 3 months of CAPOX neoadjuvantly, without adjuvant therapy?
Answer from: Medical Oncologist at Community Practice
I would! I did it in a recent patient.
Sign in or Register to read more
20161
Related Questions
Are there any data (retrospective or otherwise) on the watch and wait approach in patients who achieve cCR after CRT without consolidation chemotherapy?
Is there any circumstance where you would consider bevacizumab in patients with locally advanced colorectal cancer with rectouterine fistula?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
When treating rectal cancer with TNT and induction chemotherapy first, do you repeat pelvic MRI prior to planning for chemoradiation?
What stroke symptoms would lead you to avoid using oxaliplatin in a patient with metastatic colon cancer and a recent stroke?
How was treatment response assessed on the PROSPECT trial?
How do you approach an isolated metastasis to left supraclavicular node in rectal cancer treated with TNT with FOLFOX regimen followed by long course radiation?
Would you consider circulating DNA assay in resected node-negative deficient MMR colon cancer off-trial to guide your treatment?